Early trial results show reduced frequency and intensity of migraine attacks after single dose of psilocybin
Psilocybin, the active ingredient in psychedelic mushrooms, shows promise for the transitional treatment of episodic migraines in early clinical trials, according to a review from Yale School of Medicine's Emmanuelle Schindler, ...